In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals in Depth: March 2010

Executive Summary

GSK penned a $563 million deal with Cellzome for rights to the latter's epigenetics platform. Leading M&A was Teva's $4.5 billion bid for ratiopharm. Biopharma financing dollars rebounded, with notable private transactions including Archimedes's $100 million venture financing, and a $75 million PIPE that Lexicon did concurrent with a $111 million follow-on. Mindray's $151 million FOPO was responsible for over half of all device dollars.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts